The Small Biotech Scaring Big Pharma
There's one tiny biotech on the verge of a breakthrough dementia treatment...
Biogen, the only biotech to get a new Alzheimer's drug approved in the past 20 years, made a $1 billion investment in this company.
"The Buck Stops Here,"
This message is a paid advertisement sent on behalf of Behind the Markets, a third-party advertiser of MarketBeat. Why did I receive this email?
If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com or leave us a voicemail at (844) 978-6257.
If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.
© 2006-2023 American Consumer News, LLC dba MarketBeat. 326 E 8th St #105, Sioux Falls, SD 57103. United States.
No comments:
Post a Comment